Aktuellt
SENASTE
Redeye comments on the ADVANCE II data update published as an abstract ahead of presentation at the Annual American Society of Hematology Meeting on December 11th. We believe the presented data confirm DCP-001’s safety and constitute an encouraging early hint at DCP-001 contributing to eliminating or controlling minimal residual disease in AML patients.
LÄS MER
